Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- TNF super-family TNFSF-18 Activation-inducible TNF-Related Ligand IgG-2a costimulation TL6 TL-6
- Product Overview:
Glucocorticoid-induced TNF-related ligand (GITRL), also known as TNF superfamily member 18 (TNFSF18), is a type II transmembrane glycoprotein and member of the TNF superfamily with roles in adaptive immunity.{56065} It is composed of an N-terminal cytoplasmic domain, a transmembrane domain, and a C-terminal extracellular domain that binds to its receptor GITR (Item No. 32017) on T cells to regulate their activity. GITRL is expressed on professional and non-professional antigen-presenting cells, including B cells, monocytes, unstimulated myeloid dendritic cells, and plasmacytoid dendritic cell precursors, as well as microvascular-derived endothelial cells. GITRL co-stimulation increases activation and proliferation of T cell receptor-triggered effector T cells. It also enhances the activity of effector T cells by binding to regulatory T cells and inhibiting their activity. Upregulation of dendritic cell Gitrl levels suppresses regulatory T cell function, enhances effector T cell function, and delays tumor progression in a murine Lewis lung carcinoma model.{53754} Serum and synovial fluid levels of GITRL are increased and positively correlated with autoantibody production in patients with rheumatoid arthritis.{53755} Serum levels of GITRL are positively correlated with disease progression in patients with Sjögren syndrome.{53756} Cayman’s GITRL Extracellular Domain (human, recombinant) protein is a disulfide-linked homodimer. The reduced monomer, comprised of the GITRL extracellular domain (amino acids 72-199) fused to mouse IgG2a Fc at its C-terminus, consists of 361 amino acids and has a calculated molecular weight of 40.9 kDa. As a result of glycosylation, the monomer migrates at approximately 45 kDa by SDS-PAGE under reducing conditions.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.